文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

AKIpredictor:成人危重症患者急性肾损伤在线预后计算器的开发、验证及与血清NGAL的比较

AKIpredictor, an online prognostic calculator for acute kidney injury in adult critically ill patients: development, validation and comparison to serum neutrophil gelatinase-associated lipocalin.
PubMed 文献 · Intensive Care Med · 2017-01-27
一句话结论基于常规临床信息的AKI预测模型可在ICU入科前及入科时预测AKI,性能优于入ICU时测得的血清NGAL,模型已在线提供(AKI-123模型)。

本研究基于大型多中心EPaNIC数据库,开发并验证了成人ICU患者AKI预测模型,并通过在线预后计算器提供使用。模型开发队列n=2123,验证队列n=2367,分别基于入ICU前、入ICU时、入ICU后1天及纳入首个24小时监测数据建立模型。主要结局为比较模型与NGAL对ICU住院第一周内任何AKI(AKI-123)及AKI 2或3期(AKI-23)的预测性能。验证队列AKI-123患病率29%、AKI-23患病率15%;入ICU前AKI-123模型(含年龄、基线血清肌酐、糖尿病、入院类型)AUC 0.75(95%CI 0.75-0.75),AKI-23模型另加身高体重AUC 0.77(95%CI 0.77-0.77);随数据逐步完善,24小时后AKI-123 AUC达0.82(95%CI 0.82-0.82)、AKI-23 AUC达0.84(95%CI 0.83-0.84);NGAL判别力较低,AKI-123 AUC 0.74(95%CI 0.74-0.74)、AKI-23 AUC 0.79(95%CI 0.79-0.79)。结论认为AKI可仅用常规收集的临床信息早期预测,且性能优于入ICU时测得的NGAL,AKI-123模型可在http://akipredictor.com/获取。

要点

  • 验证队列中ICU第一周任何AKI(AKI-123)患病率29%,AKI 2或3期(AKI-23)患病率15%。
  • 入ICU前AKI-123模型含年龄、基线血清肌酐、糖尿病及入院类型,AUC 0.75(95%CI 0.75-0.75)。
  • 入ICU前AKI-23模型另加身高体重,AUC 0.77(95%CI 0.77-0.77)。
  • 纳入首个24小时数据后AKI-123模型AUC升至0.82(95%CI 0.82-0.82),AKI-23模型AUC升至0.84(95%CI 0.83-0.84)。
  • 入ICU时血清NGAL判别力较低:AKI-123 AUC 0.74(95%CI 0.74-0.74),AKI-23 AUC 0.79(95%CI 0.79-0.79)。

适用人群与场景

  • 成人ICU患者,来自大型多中心EPaNIC数据库,模型开发队列n=2123、验证队列n=2367。

研究设计与关键结果

  • 研究类型:基于大型多中心EPaNIC数据库的预测模型开发与验证研究,开发队列n=2123、验证队列n=2367;主要结局为比较模型与NGAL对ICU住院第一周内任何AKI(AKI-123)及AKI 2或3期(AKI-23)的预测性能。
  • 验证队列AKI-123患病率29%,AKI-23患病率15%。
  • 入ICU前AKI-123模型含年龄、基线血清肌酐、糖尿病及入院类型(内科/外科、急诊/择期),AUC 0.75(95%CI 0.75-0.75);AKI-23模型另加身高体重,AUC 0.77(95%CI 0.77-0.77)。
  • 随数据逐步完善,24小时后AKI-123模型AUC达0.82(95%CI 0.82-0.82),AKI-23模型AUC达0.84(95%CI 0.83-0.84)。
  • 入ICU时血清NGAL判别力较低:AKI-123 AUC 0.74(95%CI 0.74-0.74),AKI-23 AUC 0.79(95%CI 0.79-0.79)。

证据类型、等级与局限

  • 证据类型:基于EPaNIC数据库的预测模型开发与验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,AKI可仅用常规收集的临床信息早期预测,且模型性能优于入ICU时测得的NGAL。
  • AKI-123模型可在http://akipredictor.com/获取使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Early diagnosis of acute kidney injury (AKI) remains a major challenge. We developed and validated AKI prediction models in adult ICU patients and made these models available via an online prognostic calculator. We compared predictive performance against serum neutrophil gelatinase-associated lipocalin (NGAL) levels at ICU admission.

METHODS: Analysis of the large multicenter EPaNIC database. Model development (n = 2123) and validation (n = 2367) were based on clinical information available (1) before and (2) upon ICU admission, (3) after 1 day in ICU and (4) including additional monitoring data from the first 24 h. The primary outcome was a comparison of the predictive performance between models and NGAL for the development of any AKI (AKI-123) and AKI stages 2 or 3 (AKI-23) during the first week of ICU stay.

RESULTS: Validation cohort prevalence was 29% for AKI-123 and 15% for AKI-23. The AKI-123 model before ICU admission included age, baseline serum creatinine, diabetes and type of admission (medical/surgical, emergency/planned) and had an AUC of 0.75 (95% CI 0.75-0.75). The AKI-23 model additionally included height and weight (AUC 0.77 (95% CI 0.77-0.77)). Performance consistently improved with progressive data availability to AUCs of 0.82 (95% CI 0.82-0.82) for AKI-123 and 0.84 (95% CI 0.83-0.84) for AKI-23 after 24 h. NGAL was less discriminant with AUCs of 0.74 (95% CI 0.74-0.74) for AKI-123 and 0.79 (95% CI 0.79-0.79) for AKI-23.

CONCLUSIONS: AKI can be predicted early with models that only use routinely collected clinical information and outperform NGAL measured at ICU admission. The AKI-123 models are available at http://akipredictor.com/ . Trial registration Clinical Trials.gov NCT00512122.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Flechet M, Güiza F, Schetz M, et al. AKIpredictor, an online prognostic calculator for acute kidney injury in adult critically ill patients: development, validation and comparison to serum neutrophil gelatinase-associated lipocalin. Intensive Care Med. 2017. PMID: 28130688. doi:10.1007/s00134-017-4678-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。